← Back to Search

Tetracycline Antibiotic

Minocycline for High Blood Pressure

Phase 2

Waitlist Available

Led By Carl Pepine, MD

Research Sponsored by University of Florida

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

History of intestinal surgery, inflammatory bowel disease, celiac disease, lactose intolerance, chronic pancreatitis or other malabsorption disorder

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change in baseline to 24 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial will test whether minocycline, which is used to treat hypertension, is associated with a decrease in activated microglia in central nervous system autonomic regions.

Who is the study for?

This trial is for individuals with drug-resistant high blood pressure who are already part of another study (NCT02133885). Participants must be willing to travel to Montreal, Canada for brain imaging and testing. They should not be pregnant or have been so in the last 6 months, nor taking certain medications that could affect the study's outcome.

What is being tested?

The trial is studying whether Minocycline can lower blood pressure by reducing microglia activation in the brain. This will be measured using advanced imaging techniques like PET and MRI scans alongside Autonomic Nervous System Testing.

What are the potential side effects?

While specific side effects are not listed here, Minocycline commonly causes dizziness, fatigue, headache, unsteadiness, and may affect digestion. It can also lead to changes in skin color and serious allergic reactions.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a history of digestive system issues or surgeries.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change in baseline to 24 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change in baseline to 24 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and change in baseline to 24 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

MRI changes in the paraventricular nucleus

PET changes in the paraventricular nucleus

Side effects data

From 2016 Phase 4 trial • 10 Patients • NCT02124811

40%

Inpatient psychiatric hospitalization

20%

Hospitalization due to ischemic colitis

20%

Hypotension

100%

80%

60%

40%

20%

Study treatment Arm

Low CRP

High CRP

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: MinocyclineExperimental Treatment1 Intervention

Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Minocycline

2019

Completed Phase 4

~1070

0 / 1Eligibility criteria met